Plasma Protease C1-inhibitor Treatment Market Estimated to Flourish by 2025
According to estimations of the TMR report, the demand in the global plasma protease c1-inhibitor treatment market will expand at a strong 20.0% CAGR for the forecast period of 2017 to 2025, for the market to be evaluated at US$7.9 bn by 2025-end considerably up from its evaluated worth of US$1.5 bn in 2016. Key vendors in the plasma protease c1-inhibitor treatment market are engaged in expanding their product portfolio and expand their distribution networks in order to penetrate global markets. This has mandated vendors to meet the regulatory standards set by governing bodies at national and international level.
In terms of drug class, the global plasma protease C1-inhibitor treatment market witness maximum demand from the segment of c1-inhibitors that led amongst other segments in 2016. Geography-wise, the report assesses North America to be the most profitable market for plasma protease c1-inhibitor treatment, which accounted for a demand worth US$1,510.5 mn in 2017.
Growing investment for innovation in inhibitor drugs, promising pipeline drugs and novel therapies, and increasing awareness for hereditary angioedema (HAE) are primarily driving the plasma protease C1-inhibitor market through 2025.
Read Report Overview @ https://www.transparencymarketresearch.com/plasma-protease-c1inhibitor-treatment-market.html
One of the key drivers of the plasma protease C1-inhibitor treatment market is the increasing usage of plasma protease C1-inhibitor treatment drugs due to the increasing incidence of acute cases of hereditary angioedema (HAE) and prophylaxis. The emergence of C1-inhibitor is considered to be a major breakthrough among several drugs introduced in the plasma protease C1-inhibitor treatment market. Berinert is a C1-esterase inhibitor for acute HAE that received approval from the European Union in 2011. Haegarda, which is derived from C1-esterase inhibitor is approved in the U.S for routine prophylaxis as a preventive measure against HAE attacks in adolescents and adults.
Request Sample Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=33116
Increasing practice of administering prophylactic treatment process for HAE patient, demand for a new route of administration of C1-inhibitor drugs, rising demand for administering drugs subcutaneously among HAE patients are some other growth drivers of the plasma protease C1-inhibitor treatment market.
Apart from this, commercialization of drugs such as Ruconest in emerging markets of Asia Pacific is likely to boost the C1-inhibitor segment in the upcoming years.
Request Plasma Protease C1-inhibitor Treatment Market Report Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=33116
Research studies underway for the development of bradykinin B2 receptor antagonist for the treatment of HAE attacks is likely to propel the global plasma protease C1-inhibitor treatment market. At present, Firazyr is the only approved bradykinin B2 receptor for the treatment of acute HAE attack. FR 173657 is another bradykinin B2 receptor that researchers are evaluating for efficacy for acute HAE attack.
Buy Full Plasma Protease C1-inhibitor Treatment Market Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=33116<ype=S
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.
Transparency Market Research
90 State Street,
Albany NY - 12207
USA - Canada Toll Free: 866-552-3453
TMR Blog: http://www.theglobalhealthnews.com/
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Plasma Protease C1-inhibitor Treatment Market Estimated to Flourish by 2025 here
News-ID: 814740 • Views: 915
More Releases from Transparency Market Research – Pharmaceutical
Narcolepsy Market - Global Industry Trends and Forecast - 2019
Narcolepsy is a chronic neurological disorder, which is characterized by brain’s inability to control the sleep-wake cycle of an individual. This disorder is not caused due to any mental illness, but is mainly caused due to genetic abnormalities occurring from environmental factors or biologic factors. Narcoleptic individuals exhibita typical characteristic symptom, i.e. excessive daytime sleepiness (EDS), where individuals experience disturbed night sleep and abnormal daytime sleep pattern. Narcolepsy disorder is
Diabetic Macular Edema Market - Key Growth Factors and Forecast 2019
Macular edema is the condition when the fluid and proteins start collecting on or under the macula of the eye thereby resulting in swelling. Due to such swelling, a person’s central eye vision gets distorted. Macular edema is classified into two types namely cystoids macular edema (CME) and diabetic macular edema (DME). Obtain Report Details @ http://www.transparencymarketresearch.com/diabetic-macular-edema-market.html Diabetic macular edema is the major reason for loss of vision in patients
Primary Systemic Amyloidosis Market- Get Facts About Business Strategies and Fin …
Amyloids are the substance made up of abnormally formed protein in the bone marrow that gets saturated in different tissues or organs of the body. The condition is termed as amyloidosis. There are various types of amyloidosis out of which primary systemic amyloidosis are most common, these are associated with plasma cell dyscrasia and has no historical evidence of disease. Kidney, intestines, liver, heart and nerves are the common organs
Natamycin Market - Global Industry Analysis 2024
Natamycin is also known commonly as pimaricin or natacyn. It is an anti-fungal agent produced during aerobic fermentation by the Streptomyces natalensis, a bacterium found commonly in soil. Natamycin is a polyene macrolide anti-biotic Natamycin is sparingly soluble in water and required in very low concentrations. available as an odorless, white, granular powder as well as crystalline solid. Commercially, Natamycin can be produced through industrial scale fermentation process with the
More Releases for HAE
MENTAL HEALTH IN THE SPOTLIGHT AT HAE EHA CONFERENCE
Members, non-members and exhibitors attending HAE EHA’s annual conference at Holywell Park in Loughborough were given an ideal opportunity to assess and improve their strategies for dealing with mental health in the workplace by expert speakers on this growing issue. It is estimated mental health problems blight one in four of the UK population (http://www.hse.gov.uk/stress/mental-health.htm), a figure replicated last year in the construction industry according to a survey by Construction News’
Hereditary Angioedema Market is propelled by rise in hereditary angioedema (HAE) …
Some of the prominent names operating in the global hereditary angioedema market are Pharming Group NV, Shire plc, CSL Limited, Ionis Pharmaceuticals, Inc., iBio Inc., and BioCryst Pharmaceuticals, Inc. As per a report by Transparency Market Research, the global hereditary angioedema market will likely rise at a healthy 9.1% CAGR between 2017 and 2025 to become worth US$3.81 bn by 2025 from US$ 1.73 bn in 2016. Read Report Overview: https://www.transparencymarketresearch.com/hereditary-angioedema-market.html Superior Healthcare
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor (C1-INH) Deficiency) Clinical …
Market Research Hub includes new market research report "Hereditary Angioedema (HAE) (C1 Esterase Inhibitor (C1-INH) Deficiency) Clinical Trials Review, H2, 2017" to its huge collection of research reports. Request Free Sample Report- https://www.marketresearchhub.com/enquiry.php?type=S&repid=1350242 Clinical trial report, Hereditary Angioedema (HAE) (C1 Esterase Inhibitor (C1-INH) Deficiency) Global Clinical Trials Review, H2, 2017" provides an overview of Hereditary Angioedema (HAE) (C1 Esterase Inhibitor (C1-INH) Deficiency) clinical trials scenario. This report provides top line data relating
Hereditary Angioedema (HAE) Market - Future Scope Detailed Analysis to 2024
Global Hereditary Angioedema (HAE) Market: Overview Hereditary angioedema (HAE) is a rare inherited disease, which leads to repeated episodes of swelling beneath the surface of the skin. Hereditary angioedema is confined to the face, tongue, feet, legs, hands and arms. However, it sometimes leads to swelling in airways such as trachea, larynx or intestinal tract may prove out to be fatal. View Report @ http://www.transparencymarketresearch.com/hereditary-angioedema-market.html For the treatment of hereditary angioedema, currently there are
Hereditary Angioedema (HAE) - Pipeline Review, Trends, and Forecast Report 2017
Market Research Hub (MRH) has recently announced the addition of a fresh report, titled “Hereditary Angioedema (HAE) - Pipeline Review, H1 2017” to its report offerings. The report covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1196650 Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) -
Hereditary Angioedema (HAE) Market Research Report | Forecast up to 2024
Global Hereditary Angioedema (HAE) Market: Overview Hereditary angioedema (HAE) is a rare inherited disease, which leads to repeated episodes of swelling beneath the surface of the skin. Hereditary angioedema is confined to the face, tongue, feet, legs, hands and arms. However, it sometimes leads to swelling in airways such as trachea, larynx or intestinal tract may prove out to be fatal. For the treatment of hereditary angioedema, currently there are no medications